This protocol addresses liver cell adenoma in the specific molecular subtype of hepatic adenoma carrying a β-catenin mutation in exon 3 — a clinically distinct group that warrants a defined management approach.
Hepatic adenoma with a β-catenin mutation in exon 3 (HCA). β-catenin mutated HCAs carry a higher risk of malignant transformation compared with other clinical subtypes. This elevated risk is the central factor shaping the management strategy in this setting.
In this molecular subtype, the evidence supports a surgical approach as the primary intervention. The complete protocol specifies the full clinical guidance, including the indications and criteria that apply to this subtype specifically.
DOI: 10.14309/ajg.0000000000002857
β-catenin mutated HCAs are at a higher risk of malignant transformation compared with other clinical subtypes and should be resected regardless of size.
View source ↗